University of Southern California

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Southern California sits in the top decile of US sponsors by registered trial count (#55 of 15,742 sponsors by registered trial count).

617 total trials 97 currently recruiting 361 completed early-phase tilt top decile by trial count

University of Southern California: 617 sponsored US clinical trials, 97 recruiting.

University of Southern California sponsors 617 registered US clinical trials on ClinicalTrials.gov, 97 of them currently recruiting, and 361 completed. 31 of these trials are in Phase 3-4 (later-stage) and 173 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 6 trials.

Top-decile sponsor footprint

University of Southern California ranks in the top decile of sponsors by registered trial count (#55 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 33/100

361 of 466 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (77.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

617 total, page 11 of 13

COMPLETED NA

Arm Rehabilitation Study After Stroke

NCT00871715

COMPLETED NA

Avastin for PDR (Proliferative Diabetic Retinopathy)

NCT01270542

COMPLETED NA

Gestational Diabetes Follow Up Study

NCT00998595

COMPLETED NA

A Trial of Meal Replacement at a Community Diabetes Clinic Serving a Low Socioeconomic Hispanic Population

NCT01729117

COMPLETED NA

Diffusion-Weighted MRI in Staging Patients With Localized Prostate Cancer

NCT02237612

COMPLETED Phase 1

Ankle Sprains and Corticospinal Excitability

NCT00847769

COMPLETED NA

Mobile Device Biomonitoring to Prevent and Treat Obesity in Underserved Youth

NCT02017223

COMPLETED Phase 3

Pressure Ulcer Prevention Study in SCI

NCT01999816

COMPLETED Phase 4

Time Interval for Endoscopic Variceal Ligation

NCT01291277

COMPLETED Phase 2

Herbal Therapy for Treatment of Recurrent Prostate Cancer

NCT00669656

TERMINATED NA

Oral Carnitine for Cramps in Pregnancy

NCT00516516

COMPLETED NA

Green Tea in Breast Cancer Patients

NCT00949923

COMPLETED

Study of a Smart Growth Community's Effect on Prevention of Obesity in Middle-, Moderately Low- and Low-Income Families

NCT00986011

COMPLETED Phase 4

Doxycycline Effects on Inflammation in Cystic Fibrosis

NCT01323101

COMPLETED Phase 1

Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib

NCT00667147

TERMINATED Phase 1

Oral NRX 194204 in Patients With Refractory Malignancies

NCT00630760

TERMINATED Phase 4

Supplements for Controlling Resistance to Insulin

NCT00699413

COMPLETED Phase 2

Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

NCT00599170

COMPLETED Phase 2

The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial

NCT00605072

COMPLETED Phase 1

A Pilot Study of PPX in Women With Metastatic Colorectal Cancer

NCT00598247

COMPLETED NA

Theta-burst Transcranial Magnetic Stimulation

NCT00878787

COMPLETED Phase 1

BION Active Seating for Pressure Ulcer Prevention

NCT00628602

COMPLETED Phase 1

BION Treatment of Dysphagia After Radical Head-Neck Surgery

NCT00628485

TERMINATED NA

Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast

NCT00556907

COMPLETED NA

Food, Adolescence, Mood, and Exercise

NCT02015377

COMPLETED NA

Oral Contraceptive (OC) Progestin Dose and Breast Proliferation

NCT00972439

COMPLETED NA

Strength Training and Nutrition Development for African American Youth

NCT01441323

COMPLETED NA

Validation of the Stayhealthy BC1 Body Comp Analyzer

NCT01209923

COMPLETED

Use of Surface Electromyography Biofeedback to Improve Reaching in Children With Cerebral Palsy

NCT00473161

COMPLETED NA

Translational Obesity Research

NCT00787709

COMPLETED Phase 3

Treatment of Perirectal Fistula With Cutting Seton vs. Collagen Plug

NCT00450671

COMPLETED NA

Guided Imagery Intervention for Obese Latino Adolescents

NCT01895595

COMPLETED

Use of EMG to Assess Clinical Hypertonia

NCT00472914

COMPLETED NA

Multifaceted Depression and Cardiovascular Program

NCT02069912

COMPLETED

Prospective, Non-Randomized Evaluation of Carbon Dioxide Gas as a Contrast Agent in Comparison With Iodinated Contrast in Endovascular Aneurysm Repair

NCT00520416

COMPLETED Phase 4

Synchronized Intermittent Mandatory Ventilation (SIMV) Versus Nasal Intermittent Positive Pressure Ventilation (NIPPV) In Preterm Infants With Respiratory Distress

NCT00486850

COMPLETED Phase 2

Effects of Testosterone Gel on Carbohydrate and Lipid Metabolism In Elderly Obese Men

NCT00365794

TERMINATED Phase 2

A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)

NCT00183963

COMPLETED Phase 1

Vorinostat and IV Fluorouracil/Leucovorin (5FU/LV) in Patients With Metastatic Colorectal Cancer

NCT00336141

COMPLETED Phase 2

Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer

NCT01338792

COMPLETED Phase 4

A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room

NCT00457366

TERMINATED Phase 2

FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer

NCT00323011

TERMINATED NA

Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy

NCT02550119

COMPLETED NA

Trial of Oral Versus Intravenous Proton Pump Inhibitor on Intragastric pH in Patients With Bleeding Ulcers

NCT00573924

COMPLETED NA

Developing a Self-Management Program for People With Depression and Chronic Medical Illness

NCT00523029

COMPLETED

Quantification of Upper Extremity Hypertonia

NCT00285870

COMPLETED NA

Optimizing Assisted Communication Devices for Children With Motor Impairments Using a Model of Information Rate and Channel Capacity

NCT00352326

COMPLETED NA

Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI

NCT02587663

COMPLETED NA

Determining Depression Treatment Preferences of Low-Income Latinos in Primary Care Settings

NCT00260169

COMPLETED NA

FDG Positron Emission Tomography and Computed Tomography (PET-CT) in Metastatic Prostate Cancer

NCT00282906

← Previous Page 11 of 13 Next →

Phase Distribution

PhaseTrial count
Phase 1 83
Phase 2 90
Phase 3 9
Phase 4 22

What is open in the University of Southern California pipeline

97 recruiting of 617 indexed (16% open); 361 completed (59%).

Phase mix: 31 late (III/IV) vs 173 early (I/II) (early-phase heavy).

Top condition: Obesity (6 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Southern California: open-pipeline peers nationwide

Peers matched on 617 registered trials and 16% open enrollment, not the therapeutic-area sidebar.

University of Southern California sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600800 0%5%10%15%20% Total trials Recruiting share University of Southern CaliforniaBaylor College of MedicineUS Department of Veterans AffairsUniversity of RochesterJanssen Research & DevelopmentYoungstown State UniversityRoswell Park Cancer InstituteFox Chase Cancer CenterUniversity of Oregon
University of Southern California sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Southern California sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 617 trials (± recruiting share)

Sponsors near 16% open enrollment (± trial volume)

What to do with this University of Southern California page

617 registered trials is a research-attention snapshot, not an endorsement of University of Southern California or any single study.

  • 97 of University of Southern California's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition University of Southern California studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Southern California pipeline card: 617 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.